BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets.